跳至主要内容
临床试验/NL-OMON55311
NL-OMON55311尚未招募3 期

Sentinel lymph node (SLN) detection in early oral cancer using Gallium-68-Tilmanocept PET/CT - SEAGATE study

niversitair Medisch Centrum Utrecht0 个研究点目标入组 94 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
尚未招募
发起方
入组人数
94

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational invasive

入排标准

年龄范围
18 至 99(—)

入选标准

  • In order to be eligible to participate in this study, a subject must meet all
  • of the following criteria:
  • 1. The patient has provided written informed consent authorization before
  • participating in the study.
  • 2. The patient has a diagnosis of primary oral squamous cell carcinoma that is
  • anatomically located in: mucosal lip, buccal mucosa, lower alveolar ridge,
  • upper alveolar ridge, retromolar gingival (retromolar trigone),
  • floor-of-the-mouth, hard palate or oral (mobile) tongue.
  • 3. Clinical TNM-stage is T1-T2 and T3 (only when T3 is assessed based on tumor
  • dimensions of >2 cm and <=4 cm with DOI >10 mm), N0, M0 (see Appendix 6: TNM
  • 4. Clinical nodal staging (N0) has been confirmed by negative results from
  • ultrasound guided fine needle aspiration cytology within 30 days of the SLN
  • 5. The patient is a candidate for transoral excision.
  • 6. Patients with prior malignancy of the head and neck area are allowed,
  • provided the patient meets both of the following criteria:
  • Underwent potentially curative therapy for all prior head and neck
  • malignancies and is deemed low risk for recurrence; and
  • No head and neck malignancy for the past five years and no evidence of
  • recurrence.
  • 7. The patient is >=18 years of age at the time of consent.
  • 8. The patient has an ECOG status of Grade 0 - 2 (see Appendix 7: Performance
  • Status Criteria).

排除标准

  • A potential subject who meets any of the following criteria will be excluded
  • from participation in this study:
  • 1. The patient has a diagnosis of squamous cell carcinoma of the head and neck
  • in the following anatomical areas: non-mobile base of the tongue, oropharynx,
  • nasopharynx, hy-popharynx, and larynx.
  • 2. The patient is incapacitated.
  • 3. The patient has had a previous allergic reaction after administration of a
  • radionuclide trac-er.
  • 4. The patient has had other nuclear imaging studies, conducted within 2 days
  • (48 hours) of injection.
  • 5. The patient has clinical or radiological evidence of metastatic cancer to
  • the regional lymph nodes.
  • 6. The patient has a history of neck dissection, or gross injury to the neck
  • that would pre-clude reasonable surgical dissection for this trial, or
  • radiotherapy to the neck.
  • 7. The patient is actively receiving systemic cytotoxic chemotherapy.
  • 8. The patient is on immunosuppressive, anti-monocyte, or immunomodulatory

研究者

发起方
niversitair Medisch Centrum Utrecht

相似试验